Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Abstract
Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic antitumor immune responses. T-VEC was compared with GM-CSF in patients with unresected stage IIIB to IV melanoma in a randomized open-label phase III trial.Patients with injectable melanoma that was not surgically...
Paper Details
Title
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Published Date
Sep 1, 2015
Journal
Volume
33
Issue
25
Pages
2780 - 2788
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History